Increased access to Elocta (efmoroctocog alfa) on NHS through lifting of previous volume restrictions

Many people with haemophilia A in UK had restricted access to the drug with a finite volume available under previous agreement. Sobi UK and NHS have come to a new agreement allowing physicians to prescribe the most suitable therapies and tailor approaches for patients.